(2S)-2-[[(1S)-1-carboxy-5-[[4-(carboxymethyl)phenyl]carbamoylamino]pentyl]carbamoylamino]pentanedioic acid | 1610414-01-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[[(1S)-1-carboxy-5-[[4-(carboxymethyl)phenyl]carbamoylamino]pentyl]carbamoylamino]pentanedioic acid
• CAS: 1610414-01-1
• 化学式: C₂₁H₂₈N₄O₁₀
• 分子量: 496.474
• InChiKey: VSUSNUCKWPAREJ-GJZGRUSLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  35
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  232
• 氢给体数：
  8
• 氢受体数：
  10

文献信息

• [EN] CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS<br/>[FR] CONJUGUÉS POUR TRAITER LES MALADIES PROVOQUÉES PAR DES CELLULES EXPRIMANT PSMA
  申请人：ENDOCYTE INC

  公开号：WO2014078484A1

  公开（公告）日：2014-05-22

  The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

  本发明涉及对病原细胞群体进行诊断、成像和/或治疗。具体来说，本发明涉及利用能够靶向PSMA表达细胞的化合物对由PSMA表达细胞引起的疾病，如前列腺癌细胞，进行诊断、成像和/或治疗。
• PSMA LIGAND-CONTAINING CONJUGATES FOR THE TREATMENT OF PROSTATE CANCER
  申请人：Endocyte, Inc.

  公开号：EP3858341A1

  公开（公告）日：2021-08-04

  The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

  本发明涉及致病细胞群的诊断、成像和/或治疗。特别是，本发明涉及使用能够靶向 PSMA 表达细胞的化合物诊断、成像和/或治疗由 PSMA 表达细胞（如前列腺癌细胞）引起的疾病。
• CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
  申请人：Endocyte, Inc.

  公开号：EP3875082A1

  公开（公告）日：2021-09-08

  The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using a conjugate of the general formula B-L-(D)n as further defined in the claims.

  本发明涉及致病细胞群的诊断、成像和/或治疗。特别是，本发明涉及使用权利要求书中进一步定义的通式 B-L-(D)n轭合物对表达 PSMA 的细胞（如前列腺癌细胞）引起的疾病进行诊断、成像和/或治疗。
• Conjugates for treating diseases caused by PSMA expressing cells
  申请人：ENDOCYTE, INC.

  公开号：US10912840B2

  公开（公告）日：2021-02-09

  The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

  本发明涉及致病细胞群的诊断、成像和/或治疗。特别是，本发明涉及使用能够靶向 PSMA 表达细胞的化合物诊断、成像和/或治疗由 PSMA 表达细胞（如前列腺癌细胞）引起的疾病。
• US9636413B2
  申请人：——

  公开号：US9636413B2

  公开（公告）日：2017-05-02